BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 1.6% during trading on Friday . The stock traded as low as $2.35 and last traded at $2.39, with a volume of 61,233 shares changing hands. The stock had previously closed at $2.43.

Separately, Maxim Group set a $5.00 price target on shares of BrainStorm Cell Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th.

The stock has a 50 day moving average price of $2.48 and a 200 day moving average price of $2.44. The stock’s market cap is $44.58 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.13. On average, analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.